Companies in #Rheumatoid Arthritis
Found 2 companies operating in this sector.
Artiva Biotherapeutics is a clinical-stage biotechnology company founded in 2019 as a spin-out of GC Cell and headquartered in San Diego, California. The company specialized in developing allogeneic, off-the-shelf, non-genetically modified natural killer (NK) cell therapies designed to enhance monoclonal antibody-mediated B-cell depletion in autoimmune diseases and oncology. On October 27, 2026, Artiva announced the permanent discontinuation of its lead candidate AlloNK (AB-101) following insufficient clinical response durability and two Grade 5 fatal events in its Phase 2a trial, enacted a 94% workforce reduction, and engaged Leerink Partners to evaluate strategic alternatives while managing approximately $319.1 million in cash and investments.
Cullinan Therapeutics is a Cambridge, Massachusetts-based clinical-stage biopharmaceutical company developing targeted therapies for autoimmune diseases and cancer. Its clinical-stage portfolio includes CLN-978, a wholly owned CD19xCD3 bispecific T cell engager being studied as an off-the-shelf subcutaneous therapy for rheumatoid arthritis, systemic lupus erythematosus and Sjögren's disease, and zipalertinib, a brain-penetrant EGFR exon 20 insertion inhibitor developed in partnership with Taiho Oncology for non-small cell lung cancer that reported positive Phase 3 REZILIENT3 results in September 2026. The company was founded in 2016, listed on Nasdaq in January 2021, and is led by President and Chief Executive Officer Nadim Ahmed.